A Comprehensive Comparison\n\nSmall to mid-cap biotech stocks are known for their high-risk, high-reward potential. Their volatile nature can make them a tough sell in a turbulent market. Two popular stocks in this category, Iovance Biotherapeutics and Viking Therapeutics, have caught the attention of social media users. \n\nIovance Biotherapeutics is a biotech company focused on developing personalized anti-cancer treatments for areas of high unmet medical need. Their lead candidate, lifileucel, is currently under review with the FDA for an advanced form of skin cancer. The company’s innovative approach to cancer treatment has garnered significant attention and support from investors. The company’s cash runway is estimated to last until 2025, potentially leading to a capital raise in the first half of next year. This could result in dilution for current shareholders, which is a risk to consider.\n\nOn the other hand, Viking Therapeutics is pursuing a $7 billion to $10 billion market opportunity with its weight-loss drug VK2735. The company’s potential for a buyout has also attracted investors, as they would stand to make a significant profit if a larger pharmaceutical company were to acquire them. Viking will have to compete against established market leaders like Eli Lilly and Novo Nordisk. This could make it challenging for them to gain a significant market share, and their buyout odds are moderate to high. Additionally, the company is nearing an inflection point in their R&D spend and business strategy, which could lead to increased volatility in their stock price.\n\nThe high degree of uncertainty surrounding their products makes it difficult to predict their upside potential. Therefore, the question becomes which stock is less likely to lose you money over the next five to 10 years.”
” Biotech Stocks IOVA and VKTX: A Comprehensive Comparison\n\nSmall to mid-cap biotech stocks are known for their high-risk, high-reward potential. Their volatile nature can make them a tough sell in a turbulent market. Two popular stocks in this category, Iovance Biotherapeutics and Viking Therapeutics, have caught the attention of social media users. \n\nIovance Biotherapeutics is a biotech company focused on developing personalized anti-cancer treatments for areas of high unmet medical need. Their lead candidate, lifileucel, is currently under review with the FDA for an advanced form of skin cancer. The company’s innovative approach to cancer treatment has garnered significant attention and support from investors. The company’s cash runway is estimated to last until 2025, potentially leading to a capital raise in the first half of next year. This could result in dilution for current shareholders, which is a risk to consider.\n\nOn the other hand, Viking Therapeutics is pursuing a $7 billion to $10 billion market opportunity with its weight-loss drug VK2735. The company’s potential for a buyout has also attracted investors, as they would stand to make a significant profit if a larger pharmaceutical company were to acquire them. Viking will have to compete against established market leaders like Eli Lilly and Novo Nordisk. This could make it challenging for them to gain a significant market share, and their buyout odds are moderate to high. Additionally, the company is nearing an inflection point in their R&D spend and business strategy, which could lead to increased volatility in their stock price.\n\nThe high degree of uncertainty surrounding their products makes it difficult to predict their upside potential. Therefore, the question becomes which stock is less likely to lose you money over the next five to 10 years.”$IOVA2023-12-15T06:28:09.348Z
